** Shares of Emergent BioSolutions rise 12.6% to $6.88 premarket
** Co says it has secured about $400 mln in orders for 2024 and 2025 for its vaccinia virus, smallpox and mpox vaccines
** EBS says this includes the previously disclosed contract from the U.S. government to procure the vaccines, valued at more than $250 mln
** Says to date in 2024, customer orders of nearly $210 mln have been delivered for ACAM2000 - its smallpox and mpox vaccine - and CNJ-016 - its vaccine for vaccinia virus
** For the remainder of 2024 and into 2025, co says it is confirmed to deliver over $185 mln in ACAM2000 and CNJ-016 orders
** Up to last close, stock more than doubled YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。